A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe COVID-19 pneumonia and could be used to treat other respiratory infections, according to clinical trial results. The study found that the drug dornase alfa reduced hyper-inflammation in COVID-19 pneumonia patients, which occurs when the body's immune system reacts too strongly and can lead to tissue damage and death. Since the beginning of the COVID-19 pandemic, the proportion of SARS-CoV-2 infections that result in death has fallen. This is partly down to increased immunity from prior infection or vaccination, as well as improved treatments such as dexamethasone....